Data Provision Notice to provide NHS Digital with cancer data from the Public Health England (PHE) controlled Cancer Registrations, Radiotherapy, Systemic Anti-Cancer Therapy and Rapid Cancer Registrations data sets.
The National Cancer Programme has identified a requirement for expert analyses to support policy setting, service planning and recovery modelling as well as quantifying the longer term implications, and understanding the direct and indirect impact of the COVID-19 pandemic on the NHS and cancer patient outcomes.
The data to be supplied to NHS Digital by Public Health England will be used in collaboration with other stakeholders to coordinate better data linkage, tracking and analysis across the patient pathway from primary through to secondary care and outcome.
The overarching collaboration will answer questions against the following themes:
How is cancer management being modified in response to the pandemic?
What are the reasons for changes in the management of individual patients?
What effect will these changes have on patient outcomes?
What are the risks of COVID-19 infection and death for patients having cancer treatment during the pandemic?
Update: 30 November 2020: the Data Provision Notice has been updated to reflect the use of the cancer data for COVID-19 research purposes, facilitated by NHS Digital's Trusted Research Environment (TRE). The cancer data assets are necessary to enable research into the effects of COVID-19 on cancer referrals, services, diagnosis, pathways, treatments, and outcomes. Data will now be supplied by Public Health England on an ongoing basis.
Scope of the collection
This Notice is served on:
Public Health England
in respect of data relating to:
Systemic Anti-Cancer Therapy
Rapid Cancer Registrations.
Legal basis for provision of data
NHS Digital has been directed by the Secretary of State for Health and Social Care to establish and operate information systems to collect and analyse data in connection with COVID-19.